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Abstract The purpose of this study was to investigate the
safety, tolerability, and pharmacokinetics of motesanib
when combined with docetaxel or paclitaxel in patients
with metastatic breast cancer. In this open-label, dose-
finding, phase 1b study, patients received motesanib 50 or
125-mg orally once daily (QD), beginning day 3 of cycle 1
of chemotherapy, continuously in combination with either
paclitaxel 90 mg/m2 on days 1, 8, and 15 every 28-day
cycle (Arm A) or docetaxel 100 mg/m2 on day 1 every
21-day cycle (Arm B). Dose escalation to motesanib
125 mg QD occurred if the incidence of dose-limiting
toxicities (DLTs, primary endpoint) was B33 %. If the
maximum tolerated dose (MTD) of motesanib was estab-
lished in Arm B, additional patients could receive
motesanib at the MTD plus docetaxel 75 mg/m2. Forty-six
patients were enrolled and 45 received C1 dose of
motesanib. The incidence of DLTs was \33 % in all
cohorts; thus, motesanib 125 mg QD was established as the
MTD. Seven patients (16 %) had grade 3 motesanib-rela-
ted adverse events including cholecystitis (2 patients) and
hypertension (2 patients). Pharmacokinetic parameters of
motesanib were similar to those reported in previous
studies. The objective response rate was 56 % among
patients with measurable disease at baseline who received
motesanib in combination with taxane-based chemother-
apy. The addition of motesanib to either paclitaxel or
docetaxel was generally tolerable up to the 125-mg QD
dose of motesanib. The objective response rate of 56 %
suggests a potential benefit of motesanib in combination
with taxane-based chemotherapy.
Keywords Motesanib  Breast cancer  Angiogenesis 
VEGF  Chemotherapy
Introduction
Although there has been a significant decline in breast
cancer mortality over the last decade, up to 40 % of
patients will develop metastatic breast cancer (MBC), for
which there remains no curative therapy. Many therapeutic
agents effectively treat MBC; however, the overall duration
of response remains far from ideal. The median survival
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from diagnosis for triple negative MBC is approximately 2
to 3 years and for estrogen receptor-positive/progesterone
receptor-positive disease, approximately 5 years [1]. Thus,
the development of new therapies to treat MBC remains
critically important.
Angiogenesis is essential for breast cancer development
and metastasis [2], and high tumor levels of the proangi-
ogenic cytokine vascular endothelial growth factor (VEGF)
are predictive of poor clinical outcomes in patients with
breast cancer [3, 4]. The VEGF signaling pathway has thus
become a promising target, and agents targeting this
pathway have been shown to improve outcomes in patients
with MBC [5].
Motesanib is an orally administered, small-molecule
antagonist of VEGF receptors (VEGFR) 1, 2, and 3;
platelet-derived growth factor receptor (PDGFR); and Kit
[6]. Treatment with motesanib was tolerable and showed
antitumor activity when administered as monotherapy to
patients with advanced solid tumors [7, 8] and in combi-
nation with either chemotherapy or an anti-epidermal
growth factor receptor antibody in patients with non-small-
cell lung cancer (NSCLC) [9]. In tumor xenograft models
of human breast cancer, treatment with motesanib resulted
in reductions in tumor growth and tumor blood vessel
density [10]. Moreover, additive reductions in tumor
growth were achieved when motesanib was combined with
docetaxel [10], possibly as a result of VEGF pathway
blockade enhancing (and/or conserving) the antiangiogenic
activity of the taxane [11]. Potentially, the combination of
motesanib with taxane chemotherapy may have activity in
patients with MBC. The objective of this phase 1b study
was to investigate the safety, tolerability, and pharmaco-
kinetics of motesanib when combined with taxanes
(docetaxel or paclitaxel) in patients with MBC.
Materials and methods
Patients
Female patients C18 years old were eligible if they had
confirmed measurable or nonmeasurable [per Response
Evaluation Criteria in Solid Tumors (RECIST) v1.0 [12]]
adenocarcinoma of the breast with locally recurrent or
metastatic disease, Eastern Cooperative Oncology Group
performance status of 0/1, and adequate organ function.
Exclusion criteria included[1 prior chemotherapy regimen
for MBC; taxane-containing treatment within 6 months,
bevacizumab within 3 months, or VEGFR-targeted therapy
within 1 month before enrollment; uncontrolled hyperten-
sion; prior malignancy (except in situ cervical cancer or
nonmelanoma skin cancer); radiation therapy to [25 % of
bone marrow; radiation therapy for peripheral lesions
within 14 days of enrollment; central nervous system
metastases; arterial or venous thrombosis within 12 months
before enrollment; bleeding diathesis or bleeding within
14 days or major surgery within 28 days before enroll-
ment; clinically significant cardiac disease; and prior epi-
sodes of cholecystitis.
The study protocol was approved by the Institutional
Review Board/Ethics Committee at each participating
study site, and all patients provided written consent.
Study design
This open-label, dose-finding, multicenter study conducted
at 6 centers in Australia and 1 in the United States evaluated
the safety of motesanib in combination with paclitaxel or
docetaxel. Patients with locally recurrent or metastatic breast
cancer were assigned to receive motesanib in combination
with paclitaxel (Arm A), or motesanib in combination with
docetaxel (Arm B) (Fig. 1). The maximum planned sample
size (if all cohorts enrolled the maximum number of patients)
was 54. Four dose cohorts (2 in Arm A and 2 in Arm B) that
were initially planned to test lower doses of motesanib (100
and 75 mg) were not opened because the 125-mg dose was
found to be tolerable. Hence, only 46 patients were ulti-
mately enrolled in the study. The primary endpoint was the
incidence of dose-limiting toxicities (DLTs). Secondary
endpoints included the incidence of adverse events (AEs);
pharmacokinetics of motesanib, paclitaxel, and docetaxel;
objective tumor response (per RECIST v1.0) [12]; and
duration of response. Evaluation of pharmacodynamic bio-
markers was an exploratory endpoint.
Maximum tolerated dose (MTD) and DLT
The MTD was defined as the highest dose of motesanib
with an observed incidence of DLT in B33 % of patients
per cohort.
A DLT was defined as any grade 3 or 4 hematologic or
nonhematologic toxicity (except alopecia) occurring during
cycle 1 that was related to motesanib or the combination of
motesanib plus chemotherapy. Fatigue, nausea, diarrhea,
vomiting, neutropenia, febrile neutropenia, neuropathy,
thrombocytopenia, anemia, hypertension, and aspartate
aminotransferase (AST) or alanine aminotransferase (ALT)
elevations were only considered DLTs if the following
conditions were met: grade 3 fatigue [7 days or grade 4
fatigue; grade 3 or 4 nausea, diarrhea, or vomiting despite
maximum supportive care; grade 3 or 4 neutropenia with
fever C38.5 C; grade 4 neutropenia (absolute neutrophil
count \0.5 9 109/L) for [7 days; grade 4 thrombocyto-
penia (platelet count \25 9 109/L) for [7 days; grade 4
anemia; grade 4 hypertension; or AST or ALT [ 10 times
the upper limit of normal.
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Administration of study drugs and dose escalation
Patients were assigned to receive motesanib (Amgen Inc.,
Thousand Oaks, CA) plus either paclitaxel or docetaxel.
Motesanib 125 mg administered orally once daily (QD)
was the MTD in the first-in-human single-agent motesanib
study [7] and was the maximum dose for this study.
Patients received 1 of 2 doses of motesanib (50 or 125 mg)
self administered orally QD beginning day 3 of cycle 1,
and then from day 1 of subsequent cycles (Fig. 1).
Motesanib was administered with paclitaxel 90 mg/m2
[intravenously (IV) over 1 h ± 15 min] on days 1, 8, and
15 every 28-day cycle (Arm A) or docetaxel 100 mg/m2 or
75 mg/m2 (IV over 1 h ± 15 min) on day 1 every 21-day
cycle (Arm B). Patients receiving motesanib plus docetaxel
100 mg/m2 received myeloid growth factor support as
primary prophylaxis for febrile neutropenia.
Up to 6 patients were enrolled in each arm at the starting
dose of motesanib 50 mg QD. Dose escalation to motesa-
nib 125 mg QD was allowed if C4 patients completed
cycle 1 with no DLTs. At least 4 patients could be enrolled
into subsequent dosing cohorts, all of which could be
expanded to acquire additional safety data. If [2 of 4
patients receiving motesanib 125 mg QD experienced a
DLT, lower doses could be explored. If the MTD of
motesanib was established in Arm B, an additional cohort
of patients could be enrolled to receive motesanib at the
MTD plus docetaxel 75 mg/m2, a commonly used dose of
docetaxel for patients with MBC in many countries; this
cohort received no myeloid growth factor support. Intra-
patient dose escalation was not allowed. Patients continued
to receive study drugs until disease progression, with-
drawal of consent, or occurrence of unacceptable toxicity.
Dose modifications
If a patient experienced a DLT, motesanib was withheld
until the toxicity resolved to either grade 1 or baseline and
then restarted with a 25-mg dose reduction. One dose
reduction per patient was allowed with the exception of
hypertension management, for which 2 dose reductions
were allowed. If the patient did not recover within 3 weeks,
study treatment was discontinued. A DLT in patients
receiving motesanib 50 mg QD would result in the dis-
continuation of study treatment.
Chemotherapy could be delayed B3 weeks for severe
toxicities. One dose reduction was allowed for paclitaxel; 2
were allowed for docetaxel. More than a 3-week delay


































































Cohort A1 / B1
Motesanib 50 mg QD +
Paclitaxel 90 mg/m2 (Arm A)
OR
Docetaxel 100 mg/m2 (Arm B)
Cohort A2 / B2
Motesanib 125 mg QD +
Paclitaxel 90 mg/m2 (Arm A)
OR
Docetaxel 100 mg/m2 (Arm B)
Cohort B3
Motesanib MTD +
Docetaxel 75 mg/m2 (Arm B)
28 days 3 working 
days
28 days (Arm A) or 21 days (Arm B) Repeat cycles 30 days
Fig. 1 Study schema. aThe sponsor and the principal investigators reviewed the safety data from each cohort to evaluate possible drug effects
and DLTs. bDisease progression or motesanib intolerability
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Blood pressure was monitored weekly for the first
6 weeks and then at each clinic visit. Investigators were
permitted to use standard antihypertensive treatments.
Motesanib was to be discontinued for reoccurrence of
symptomatic hypertension or hypertension despite maxi-
mal doses of a 4-drug antihypertensive regimen. Motesanib
was also permanently discontinued for patients with grade
4 hemorrhage, [1 grade 3 hemorrhage, grade 4 venous
thrombosis, or grade 3 or 4 arterial thrombosis.
Motesanib was withheld for patients who developed a
clinical diagnosis of cholecystitis or symptoms attributed to
gallbladder enlargement in the absence of cholecystitis.
Patients who developed hypothyroidism [elevated thyroid-
stimulating hormone (TSH) levels above upper limits of
normal and/or a low T4 level] and/or signs or symptoms of
hypothyroidism could receive thyroid hormone replace-
ment therapy (i.e., levothyroxine) according to standard
clinical care.
AE assessments
AEs were recorded and classified according to the Medical
Dictionary for Regulatory Activities and graded according
to the Common Terminology Criteria for Adverse Events
version 3.0 [13].
Pharmacokinetic and pharmacodynamic analyses
Plasma samples for pharmacokinetic analysis of motesanib
and analysis of serum placental growth factor (PLGF) and
VEGF were collected predose and at 1, 3, 6, 24 (before the
next motesanib dose), and 48 h (trough) after motesanib
administration on days 3 and 8 of cycle 1 in Arm A and on
day 3 of cycle 1 and day 1 of cycle 2 in Arm B. Plasma
samples for pharmacokinetic analysis of paclitaxel and
docetaxel were collected preinfusion and at 0.5, 1, 2, 4, 6,
24, 48, and 96 h after infusion on days 1 and 8 of cycle 1 in
Arm A and on day 1 of cycles 1 and 2 in Arm B. Samples
were analyzed at Amgen, Inc. (Thousand Oaks, CA) for
motesanib and at Bioanalytical Systems, Inc. (McMinn-
ville, OR) for paclitaxel and docetaxel using validated
analytical methods. Serum PLGF and VEGF were assessed
using multiplexed electrochemiluminescent immunoassays
(Meso-Scale Discovery, Gaithersburg, MD) as previously
described [14].
Pharmacokinetic parameters including the area under
the concentration–time curve (AUC) and the maximum and
minimum observed plasma concentrations (Cmax and Cmin)
were estimated using standard noncompartmental methods
with WinNonlin software (version 5.1.1, Pharsight Cor-
poration, Mountain View, CA). The effect of motesanib on
exposure to paclitaxel and docetaxel was investigated by
calculating the ratio point estimates for the geometric least
square mean (GLSM) values (90 % CI) of Cmax and AUC0-
inf for motesanib plus paclitaxel versus paclitaxel alone
(day 8 vs. 1) and motesanib plus docetaxel versus docetaxel
alone (cycle 2 vs. 1) using SAS PROC Mixed procedure
(SAS for Windows, version 9.1, WIN_PRO platform; SAS
Institute, Inc.). Specifically, GLSM ratios were calculated
by estimating the difference in the least squares means for
log-transformed Cmax and AUC0-inf; the ratios were then
converted back to their original scale.
Tumor-response assessment
Tumor response was assessed with either computed
tomography or magnetic resonance imaging within 28 days
of enrollment and every 2 cycles: every 8 ± 1 weeks in
Arm A and every 6 ± 1 weeks in Arm B. Bone scans were
performed every 12 ± 1 weeks if bone metastases were
present at baseline and at any time of clinical suspicion in
other patients. Tumor response was assessed by investi-
gators per modified RECIST v1.0 [12].
Statistical analyses
Safety was evaluated among all patients who received
C1 dose of motesanib. Tumor responses were recorded for
all patients with measurable disease at baseline. Duration
of response was calculated as the time from the first
objective response to disease progression or death. Patients
who responded and did not progress or die while on study
were censored on the date of their last assessment. Pro-
gression-free survival (PFS) was calculated as the time
from the first day of study treatment and the date when
disease progression was determined or death. Patients who




Forty-six patients were enrolled between May 2006 and
August 2008. One patient was screened but withdrew
consent before receiving study treatment. Forty-five
patients received C1 dose of motesanib. Patient demo-
graphics and baseline characteristics are summarized in
Table 1.
Forty-two patients discontinued motesanib because of
disease progression (n = 23, 50 %), AE (n = 15, 33 %),
administrative decision (n = 2, 4 %), and withdrawal of
consent (n = 2, 4 %). Three patients were receiving
motesanib at the time of data analysis. Ten of 19 patients in
cohort B2 and 8/12 patients in cohort B3 had dose
244 Breast Cancer Res Treat (2012) 135:241–252
123
reductions during the study; dose reductions were not
required in other cohorts. The median follow-up time was
29.5 weeks (range 1–94 weeks).
DLTs and MTD
Five patients received motesanib 50 mg QD plus paclitaxel
90 mg/m2 (Cohort A1), and 5 received motesanib 50 mg
QD plus docetaxel 100 mg/m2 (Cohort B1). None of these
patients had a DLT; therefore, 5 patients were enrolled into
Cohort A2 and received motesanib 125 mg QD plus pac-
litaxel 90 mg/m2 and 19 were enrolled into Cohort B2 and
received motesanib 125 mg QD plus docetaxel 100 mg/m2.
There were no DLTs in Cohort A2; DLTs occurred in 3
patients (16 %) in Cohort B2, 2 with grade 3 fatigue
[7 days and 1 with grade 3 migraine. Motesanib 125 mg
QD was, therefore, established as the MTD, and 12 addi-
tional patients were enrolled into Cohort B3 and received
motesanib 125 mg QD plus docetaxel 75 mg/m2; no DLTs
occurred in this cohort.
Adverse events
All 45 patients experienced C1 treatment-emergent AE
during the study, of whom 29 (64 %), 6 (13 %), and 2
(4 %) had grade 3, 4, or 5 events, respectively. Grade 4
AEs included neutropenia (Cohort A2, 1 patient; Cohort
B2, 2 patients; and Cohort B3, 1 patient), pneumonia and
acute respiratory failure (Cohort B2, 1 patient), and pyrexia
(Cohort B3, 1 patient). Grade 5 AEs occurred in 1 patient
(Cohort B1) who experienced grade 4 thrombocytopenia,
influenza, and neutropenic sepsis and later died of bron-
chopneumonia; and 1 in Cohort B2 who experienced grade
3 migraine, hypertension, fatigue, diplopia, asthenia,
hyperbilirubinemia, and decreased level of consciousness
(after a fall) and died of multiorgan failure. None of the
grade 4 or 5 AEs were considered related to treatment with
motesanib.
Forty patients (89 %) experienced C1 motesanib-related
treatment-emergent AE, 19 of whom (42 %) had grade 3
motesanib-related AEs, the most common being fatigue and
diarrhea (Table 2). The incidence of grade 3 motesanib-
related AEs was approximately 2-fold higher among patients
who received motesanib 125 mg QD versus 50 mg QD.
Twenty-seven patients (60 %) had treatment-emergent
AEs of interest deemed related to motesanib, 7 of whom
(16 %) had grade 3 AEs (Table 2). The patients with grade
3 cholecystitis, grade 3 decreased ejection fraction, or
grade 3 increased blood amylase were removed from the
study. The 2 patients with hypertension had recurrent
hypertension (despite medication) and had their dose of
motesanib altered. Each of these AEs occurred after the
DLT assessment window.
Grade 2 hypertension deemed related to motesanib was
observed in 9 patients; 2 had recurrent hypertension, and 1
was removed from the study.
Pharmacokinetics of motesanib, paclitaxel,
and docetaxel
Motesanib AUC, Cmax, and Cmin values were comparable to
those observed in previous studies (Fig. 2). Pharmacokinetic
Table 1 Patient demographics and baseline characteristics
All patients (N = 45)
Race, n (%)
White 41 (91)
Black/African American 2 (4)
Asian 1 (2)
Other 1 (2)
Age, median (range) 51.0 (28–81)












ECOG performance status, n (%)
0 28 (62)
1 17 (38)




Patients with prior chemotherapyb, n (%)
Adjuvant 32 (71)
For metastatic diseasec 5 (11)
Patients with prior hormonal therapy, n (%)
Adjuvant 19 (42)
For metastatic disease 14 (31)
Patients with prior radiotherapy, n (%) 31 (69)
Safety analysis set: all patients who received at least 1 dose of
motesanib
ECOG Eastern Cooperative Oncology Group, HER2 human epider-
mal growth factor receptor 2
a Per investigator assessment (data unavailable for 1 patient in Arm A)
b No patient received prior neoadjuvant treatment
c Patients received 1 course of prior chemotherapy
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parameters are shown in Table 3. Coadministration of
motesanib with paclitaxel increased paclitaxel Cmax by
23–45 % and increased paclitaxel AUC0-inf by 18–28 %.
Coadministration of motesanib with docetaxel did not affect
docetaxel Cmax or docetaxel AUC0-inf in Cohort B2; how-
ever, the data in Cohorts B1 and B3 showed high variability
(GLSM values ranging from 0.98 to 2.47) due to 1 patient in
each cohort with unusually high exposures during Cycle 2.
Excluding these patients from the analysis, coadministration
of motesanib did not appear to markedly affect docetaxel
exposure in Cohort B1, although Cmax increased 53 % and
AUC0-inf decreased 19 % in Cohort B3.
Pharmacodynamic biomarkers
PLGF concentrations in the serum increased 24 h
after initiation of motesanib. In all analyzed cohorts,
approximately 3-fold increases from baseline in PLGF
were maintained during treatment (Fig. 3a). VEGF con-
centrations in the serum also increased after initiation of
motesanib; however, the magnitude of this increase was
smaller than the change in PLGF, and it was transient
(Fig. 3b).
Tumor response
Thirty-two patients (71 %) had measurable disease at
baseline, and among the 31 assessed for tumor response, 30
experienced a decrease from baseline (Fig. 4). Overall, 18
of 32 patients (56 %) achieved a confirmed partial
response, 12 (38 %) had stable disease (4 for C24 weeks),
and 1 had progressive disease (Table 4). A higher inci-
dence of partial responses was observed among patients
who received the highest dose of motesanib: 3 of 4 in
Table 2 Motesanib-related AEs and events of interest
Arm A Motesanib ? paclitaxel
90 mg/m2




















Cohort B3 125 mg QD
(n = 12)
Patients with any motesanib-related
AE, n (%)a
4 (80) 4 (80) 4 (100) 17 (89) 11 (92) 40 (89)
Patients with any motesanib-related
AE of worst grade 3, n (%)b
1 (20) 2 (40) 1 (25) 9 (47) 6 (50) 19 (42)
Diarrhea 0 0 0 3 (16) 3 (25) 6 (13)
Fatigue 0 1 (20) 0 3 (16) 1 (8) 5 (11)
PPES 0 0 0 2 (11) 0 2 (4)
Anticoagulation drug level
elevated
0 1 (20) 0 0 0 1 (2)
Arthralgia 0 1 (20) 0 0 0 1 (2)
Eczema 0 0 0 1 (5) 0 1 (2)
Hypokalemia 0 0 0 1 (5) 0 1 (2)
Lethargy 0 0 0 1 (5) 0 1 (2)
Migraine 0 0 0 1 (5) 0 1 (2)
Patients with any motesanib-related
AE of interest of worst grade 3,
n (%)b
1 (20) 1 (20) 1 (25) 2 (11) 2 (17) 7 (16)
Cholecystitis 0 1 (20) 1 (25) 0 0 2 (4)
Hypertension 1 (20) 0 0 1 (5) 0 2 (4)
ALT increased 0 0 0 1 (5) 1 (8) 2 (4)
Deep vein thrombosis 0 1 (20) 0 0 0 1 (2)
Ejection fraction decreased 0 0 0 0 1 (8) 1 (2)
Blood amylase increased 1 (20) 0 0 0 0 1 (2)
AE adverse event, ALT alanine aminotransferase, CTCAE Common Terminology Criteria for Adverse Events, MedDRA Medical Dictionary of
Regulatory Activities, PPES palmar-plantar erythrodysesthesia syndrome
a MedDRA preferred terms, grade based on CTCAE version 3.0
b Some AEs occurred in the same patient
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Cohort A2, 8 of 13 in Cohort B2, and 5 of 9 in Cohort B3.
The clinical benefit rate (complete response ? partial
response ? stable disease C 24 weeks) was 69 %. The
Kaplan–Meier estimate of the median duration of response
was between 5 and 6.3 months (Table 4). Of the 13
patients with nonmeasurable disease at baseline, 10 had
stable disease, 5 with stable disease C24 weeks, and 2 had
progressive disease (Table 4).
Progression-free survival
At the time of this analysis, 29 patients had had PFS events
(Cohort A1, n = 3; A2, n = 1; B1, n = 3, B2, n = 14, B3,
n = 17). The median PFS (95 % CI) was 9.3 (3.1–21.0),
5.9 (3.4–not estimable), 6.3 (4.5–7.6), and 11.3 (5.2–12.5)
months for Cohorts A1, B1, B2, and B3, respectively.
Because only 1 PFS event occurred in Cohort A2 before
the data cutoff, median PFS could not be evaluated for this
cohort. Among the other 4 patients, 1 had a PFS event at
5.7 months, and the other 3 were on study for 5.6, 15.0, and
15.2 months without progression.
Discussion
A number of anti-VEGF pathway agents have been shown
to improve outcomes for patients with MBC when used in
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Median 246 174 96.6 131
37 11 5 19 12
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36 9 3 17 9









Fig. 2 Comparison of motesanib Cmax (a) and AUC0-inf (b) values
during cycle 1 with Cmax and AUC0-inf values obtained from previous
motesanib studies. Study 1 is the first-in-human study of motesanib in
patients with advanced solid tumors [7]; study 2 is the phase 1b study
of motesanib in combination with chemotherapy or panitumumab in
patients with NSCLC [9]
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phase 1b study, 45 patients with MBC received 2 different
doses of motesanib in combination with either paclitaxel or
docetaxel. No new safety signals were observed beyond
those already demonstrated in prior phase 1 studies with
single-agent motesanib. The MTD of motesanib in com-
bination with either paclitaxel or docetaxel was 125 mg
QD, consistent with that reported for single-agent
motesanib in patients with advanced solid tumors [7] and
in combination with platinum-containing chemotherapy
and/or panitumumab in patients with NSCLC [9].
In this study, AEs were noted that have been observed in
previous motesanib clinical trials: hypertension, deep vein
thrombosis, and cholecystitis. Of note, hypertension,
thromboembolic events, and bleeding events are known
effects of VEGF(R) inhibitors [15]. In this study, 2 patients
(4 %) experienced grade 3 hypertension that resulted in
dose modifications. The incidence of grade 3 hypertension
was less than that observed in the motesanib phase 1b
NSCLC trial [9] and in a phase 3 trial of bevacizumab
combined with paclitaxel in MBC [16] and the same as that
observed in a phase 2 trial of bevacizumab in combination
with docetaxel in MBC [17]. The overall incidence of
grade C3 thromboembolic events (2 %) was less than
observed in the motesanib phase 1b NSCLC trial and
similar to that observed in the aforementioned bev-
acizumab studies. There were no grade C3 bleeding events
in the current trial; grade 1 epistaxis was observed,
occurring in 22 % of patients overall.
Table 3 GLSM point estimates for the ratios of paclitaxel or doce-
taxel Cmax and AUC0-inf in patients treated with motesanib plus
paclitaxel or docetaxel, versus paclitaxel or docetaxel alone
Descriptive statistic Cmax (ng/mL) AUC0-inf (lg  h/mL)
Cohort A1: 50 mg motesanib ? 90 mg/m2 paclitaxel
N 5 5
GLSM 1.23 1.18
90 % CI 0.91–1.65 1.00–1.39
Cohort A2: 125 mg motesanib ? 90 mg/m2 paclitaxel
N 5 4–5
GLSM 1.45 1.28
90 % CI 1.12–1.87 1.16–1.40
Cohort B1: 50 mg motesanib ? 100 mg/m2 docetaxel
N 3–4 3–4
GLSM 2.47a 1.52a
90 % CI 0.88–6.89 0.67–3.43
Cohort B2: 125 mg motesanib ? 100 mg/m2 docetaxel
N 14–19 14–19
GLSM 0.97 0.97
90 % CI 0.72–1.29 0.77–1.22
Cohort B3: 125 mg motesanib ? 75 mg/m2 docetaxel
N 12 10–11
GLSM 1.90b 0.98b
90 % CI 1.17–3.08 0.61–1.56
AUC area under the concentration–time curve, Cmax maximum
observed plasma concentration, GLSM geometric least square mean
a High Cycle 2 mean docetaxel Cmax and AUC0-inf values and GLSM
ratios were obtained from 1 patient. When this patient is excluded
from the analysis, the resulting point estimates (90 % CIs) for the
Cmax and AUC0-inf ratios are 1.03 (0.86–1.24) and 0.82 (0.59–1.13),
respectively
b High Cycle 2 mean docetaxel Cmax and AUC0-inf values and GLSM
ratios were obtained from 1 patient. When this patient is excluded
from the GLSM analysis, the resulting point estimates (90 % CIs) for
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Motesanib 125 mg QD + 75 mg/m2 docetaxel
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Motesanib 50 mg QD + 100 mg/m2 docetaxel
Motesanib 125 mg QD + 100 mg/m2 docetaxel
Motesanib 125 mg QD + 75 mg/m2 docetaxel
Treatment Hour
96 120 504 505 507 510 528 552
1 1N= 1 1 1
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–2
1
Fig. 3 Mean (±SE) fold change from baseline in PLGF (a) and
VEGF (b) among patients receiving motesanib in combination with
paclitaxel or docetaxel. No error bars are shown where only 1 or 2
samples were evaluable for a particular time point


























Partial response (n = 19)
Patients with response assessment (N = 31)
Progressive disease (n = 1)








B1 B1 B2B3B2 B2 B3 B3 A2 B2 B2 B2 B2 A1 B2A2 A2 B3 B2B2B3 A1 B3B3 B1 B3 B2 B2 B2 B3
Fig. 4 Change from baseline in tumor measurements among patients
with measurable disease at baseline. Cohorts: A1 motesanib 50 mg
QD ? paclitaxel 90 mg/m2; A2 motesanib 125 mg QD ? paclitaxel
90 mg/m2; B1 motesanib 50 mg QD ? docetaxel 100 mg/m2; B2
motesanib 125 mg QD ? docetaxel 100 mg/m2; B3 motesanib
125 mg QD ? docetaxel 75 mg/m2. One patient in Cohort A2 had
no response assessment. SLD sum of longest diameters
Table 4 Objective tumor response
Arm A Motesanib ? paclitaxel
90 mg/m2



















Cohort B3 125 mg QD
(n = 12)
Patients with measurable
disease at baseline, n (%)
3 (60) 4 (80) 3 (75) 13 (68) 9 (75) 32 (71)
Tumor responsea, n (%)
Confirmed PR 1 (33) 3 (75) 1 (33) 8 (62) 5 (56) 18 (56)
SD 2 (67) 0 2 (67) 4 (31) 4 (44) 12 (38)
Durable
SD C 24 weeks
0 0 0 2 (15) 2 (22) 4 (13)
PD 0 0 0 1 (8) 0 1 (3)
Clinical benefit rateb,
n (%)
1 (33) 3 (75) 1 (33) 10 (77) 7 (78) 22 (69)
Duration of response,
median monthsc, (range)





2 (40) 1 (20) 1 (25) 6 (32) 3 (25) 13 (29)
Tumor responsed, n (%)
SD 2 (100) 1 (100) 1 (100) 5 (83) 1 (33) 10 (77)
Durable
SD C 24 weeks
1 (50) 1 (100) 1 (100) 2 (33) 0 (0) 5 (38)
PD 0 (0) 0 (0) 0 (0) 1 (17) 1 (33) 2 (15)
Clinical benefit rateb,
n (%)
1 (50) 1 (100) 1 (100) 2 (33) 0 (0) 5 (38)
NE not estimable, PD progressive disease, PR partial response, QD once daily, SD stable disease
a No response assessment data were available or response was reported as ‘‘unknown’’ for 1 patient in Cohort A2
b Clinical benefit rate: PR ? durable SD C 24 weeks
c Kaplan–Meier estimates. ‘‘?’’ indicates the value is a censoring time
d One patient in Cohort B3 was not evaluable for tumor response
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Grade 3 cholecystitis resulted in the discontinuation of
treatment for 2 (4 %) patients in the study. Cholecystitis
was previously reported in a phase 1b study that evaluated
motesanib in NSCLC [9] and in a study with the VEGFR
inhibitor sunitinib in renal cell carcinoma [18]. The etiol-
ogy of this toxicity is not known, and patients should be
evaluated to exclude preexisting gallbladder abnormalities
before receiving motesanib and monitored for unexpected
abdominal symptoms.
Paclitaxel and docetaxel had minimal effects on the
pharmacokinetics of motesanib. Similarly, paclitaxel had
minimal effect on motesanib pharmacokinetic parameters in
patients with NSCLC [9]. In this study, paclitaxel Cmax and
AUC0-inf values were generally higher (20–45 %) after
exposure to motesanib. Similar results were observed at the
125-mg QD motesanib dose in patients with NSCLC [9].
This effect may be due to the mild inhibitory effects of
motesanib on cytochrome P450 3A4 [19], which is involved
in the metabolism of paclitaxel [20, 21]. Despite this effect,
there appeared to be no impact on paclitaxel-related toxici-
ties. Docetaxel AUC0-inf values were generally similar, with
or without coadministration of motesanib. In contrast,
docetaxel Cmax values were higher after exposure to
motesanib in some patients likely due in part to differences in
the infusion duration: the median infusion duration was
slightly shorter during cycle 2 versus 1 for some patients,
particularly in those in Cohort B3. Due to high interpatient
variability, these results should be interpreted with caution.
The biomarker analysis showed a sustained increase in
PLGF in response to motesanib treatment. These data are
consistent with previous biomarker analyses of motesanib
studies in various tumor types, including breast cancer [14,
22, 23]. One of those studies initially showed evidence
suggesting that change in PLGF may be a predictor of
response to motesanib treatment in patients with MBC [22].
However, in the large phase 3 MONET1 study of motesanib
plus carboplatin/paclitaxel in patients with nonsquamous
NSCLC, which prospectively assessed associations between
change in PLGF and overall survival, no association
between PLGF change and outcomes was identified [24].
Although the patient numbers in our study were small,
the objective response rate of 56 % among patients with
measurable disease is promising. To put this result into
perspective, a phase 3 study of bevacizumab plus paclitaxel
in previously untreated patients with MBC reported a
response rate of 49.2 % among patients with measurable
disease [16]. In addition, bevacizumab plus paclitaxel
prolonged median PFS compared with paclitaxel alone
(11.8 vs. 5.9 months) [16].
More recently, the results of 3 large phase 3 placebo-
controlled trials in patients with human epidermal growth
factor receptor 2-negative MBC were reported: bevacizumab
or placebo plus docetaxel (AVADO) [25], bevacizumab or
placebo plus anthracycline- or taxane-based chemotherapy
or capecitabine (RIBBON-1) [26], and motesanib or bev-
acizumab or placebo plus paclitaxel (TRIO 010) [27]. The
results of AVADO and RIBBON-1 showed that the addition
of bevacizumab resulted in a statistically significant, although
modest (1.0–2.9 months), prolongation of PFS. In TRIO 010,
the addition of motesanib did not statistically significantly
improve objective response rate in comparison to paclitaxel
alone, although there was a trend toward superiority, favoring
motesanib plus paclitaxel (49 %) and bevacizumab plus
paclitaxel (52 %) compared with single-agent paclitaxel
(41 %).
Despite the somewhat disappointing results of AVADO,
RIBBON-1, and TRIO 010, VEGF(R) inhibitors have
proven benefit in other human cancers. Further, a benefit of
antiangiogenesis therapies clearly exists in breast cancer
and remains an area of active investigation. Motesanib
inhibits VEGFR1, VEGFR-2, and VEGFR-3 as well as
PDGFR and Kit, potentially offering additional benefit not
only by blocking angiogenesis but also by reducing lym-
phangiogenesis, and potentially tumor growth [28–31].
In summary, in the present phase 1b study, motesanib in
combination with taxanes was tolerable and showed a high
response rate in this population of patients with MBC.
These data warrant further exploration of motesanib in the
treatment of patients with breast cancer.
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